

Naimark Report commissioned by the hospital and its documentary base. We also had access to key Apotex and hospital documents not available to the Naimark Review. We therefore believe we had a comprehensive set, from both sides, of relevant information regarding all players in the dispute. The central conclusions of our report were independently corroborated by the Dec. 19, 2001, report issued by the College of Physicians and Surgeons of Ontario,<sup>5</sup> who had the participation of some of those very individuals who declined to participate in our inquiry.

We would encourage your readers to read our report, along with the supplement discussing events since October 2001; both can be accessed at [www.dal.ca/committeeforinquiry](http://www.dal.ca/committeeforinquiry). Contrary to the suggestion in your editorial, the rights of "the study subject who volunteers in research" are judged to be a centrally important issue in our report; indeed, they drive the wide-ranging recommendations that we hope will be taken up by all of those responsible for the well-being of research participants in Canada.

#### Patricia Baird

Professor, Department of Medical Genetics  
University Distinguished Professor  
University of British Columbia  
Vancouver, BC

#### Jon Thompson

Professor and Chair  
Department of Mathematics and Statistics  
University of New Brunswick  
Fredericton, NB

#### Jocelyn Downie

Associate Professor  
Faculties of Law and Medicine  
Dalhousie University  
Halifax, NS

#### References

- Gibson E, Baylis F, Lewis S. Dances with the pharmaceutical industry [editorial]. *CMAJ* 2002;166(4):448-50.
- Naylor CD. The deferiprone controversy: time to move on [editorial]. *CMAJ* 2002;166(4):452-3.
- Shuchman M. The Olivieri dispute: No end in sight? *CMAJ* 2002;166(4):487.
- Questions of interest [editorial]. *CMAJ* 2002;166(4):413.
- College of Physicians and Surgeons of Ontario. *Complaints Committee Decision and Reasons*, Dec.

19, 2001:17. Available: [www.caut.ca/english/bulletin/2002\\_jan/default.asp](http://www.caut.ca/english/bulletin/2002_jan/default.asp) (accessed 2002 June 7).

## Alzheimer's disease and herpes

Herpes simplex virus type 1 (HSV1) is present in latent form in the brains of a high proportion of elderly people<sup>1</sup> and is a risk factor for Alzheimer's disease in carriers of the type-4 allele of the apolipoprotein E gene (apoE-e4). ApoE-e4 is also a risk factor for cold sores.<sup>2,3</sup> We have suggested that when HSV1 is reactivated in the nervous system the resulting damage is greater in apoE-e4 carriers than in people who carry the other apoE alleles. We recently detected antibodies to HSV1 in cerebrospinal fluid, substantiating our detection of HSV1 by polymerase chain reaction and showing that it does indeed reactivate (unpublished data). A clinical trial testing a synthetic amyloid peptide as immunotherapy for Alzheimer's disease was recently halted because 4 patients developed inflammation of the brain; in "some" of these 4 patients, a virus was detected in the cerebrospinal fluid.<sup>4</sup>

The results of René Verreault and colleagues<sup>5</sup> raise the intriguing possibility that viruses other than HSV1 may directly influence Alzheimer's disease. Nonetheless, their findings could equally well be explained by an indirect effect: HSV1 reactivation can be triggered by inflammation, and vaccines would presumably prevent inflammation by preventing infection with the target virus, thus indirectly preventing HSV1 reactivation. Their study also supports the possibility that vaccination against HSV1 itself might prevent Alzheimer's disease; such vaccination is feasible now that the age at which primary infection occurs is rising. In fact, we have shown that vaccination of HSV1-infected mice with mixed HSV1 glycoproteins prevents establishment of latency in the brain.<sup>6</sup>

Finally, it would be interesting to know if the trend detected by Verreault and colleagues is dependent on the

apoE-genotype. Such dependence has also been found for patients with herpes simplex encephalitis<sup>7</sup> and for subjects infected with HIV but who have not yet developed AIDS.<sup>8</sup>

Ruth F. Itzhaki

Curtis B. Dobson

Molecular Neurobiology Laboratory  
Department of Optometry and Neuroscience  
University of Manchester Institute of Science and Technology  
Manchester, UK

#### References

- Jamieson GA, Maitland NJ, Wilcock GK, Craske J, Itzhaki RF. Latent herpes simplex virus type 1 in normal and Alzheimer's disease brains. *J Med Virol* 1991;33:224-7.
- Itzhaki RF, Lin WR, Shang D, Wilcock GK, Faragher B, Jamieson GA. Herpes simplex virus type 1 in brain and risk of Alzheimer's disease. *Lancet* 1997;349:241-4.
- Lin WR, Graham J, MacGowan SM, Wilcock GK, Itzhaki RF. Alzheimer's disease, herpes virus in brain, apolipoprotein E4 and herpes labialis. *Alzheimers Rep* 1998;1:173-8.
- Elan and AHP provide an update on the phase 2A clinical trial of AN-1792*. Dublin: Elan Corporation; 2002. Available: [www.elan.com/NewsRoom/NewsYear2002/01182002.asp?ComponentID=2330&Sour%20cePageID=2333#1](http://www.elan.com/NewsRoom/NewsYear2002/01182002.asp?ComponentID=2330&Sour%20cePageID=2333#1) (accessed 2002 Mar 8).
- Verreault R, Laurin D, Lindsay J, De Serres G. Past exposure to vaccines and subsequent risk of Alzheimer's disease. *CMAJ* 2001;165(11):1495-8.
- Lin WR, Jennings R, Smith TL, Wozniak MA, Itzhaki RF. Vaccination prevents latent HSV1 infection of mouse brain. *Neurobiol Aging* 2001;22:699-703.
- Lin WR, Wozniak MA, Esiri MM, Klenerman P, Itzhaki RF. Herpes simplex encephalitis: involvement of apolipoprotein E genotype. *J Neurol Neurosurg Psychiatry* 2001;70:117-9.
- Corder EH, Robertson K, Lannfelt L, Bogdanovic N, Eggertsen G, Wilkins J, et al. HIV-infected subjects with the E4 allele for APOE have excess dementia and peripheral neuropathy. *Nat Med* 1998;4:1182-4.

## Spinal manipulation versus mobilization

The commentary by Edzard Ernst<sup>1</sup> alerts health professionals to the possible complications of cervical manipulation. However, we feel that the commentary would have been even more clinically relevant if it had emphasized to physicians the distinction between spinal manipulation techniques and mobilization techniques. Manipulation is defined as a small-amplitude, high-velocity thrust tech-

nique — a rapid movement over which the patient has no control. Mobilizations are low-velocity techniques that can be performed in various parts of the available range based on the desired effect. Mobilization techniques have been shown to produce concurrent effects on pain, sympathetic nervous system activity, and motor activity.<sup>2-4</sup> Mobilizations can be prevented by the patient<sup>5</sup> and are generally considered far safer than manipulations. The majority of physiotherapists in Canada use mobilization techniques on the spine, as opposed to manipulation, while many have trained in both and are able to select the most appropriate technique for the patient's problem. It would be a shame if physicians eschewed this technique by misrepresenting Ernst's excellent commentary.

#### Meena Sran

Osteoporosis Program  
Children's and Women's Health Centre  
of British Columbia  
University of British Columbia  
Vancouver, BC

#### Karim Khan

Department of Family Practice  
University of British Columbia  
Vancouver, BC

#### References

1. Ernst E. Spinal manipulation: Its safety is uncertain [editorial]. *CMAJ* 2002;166(1):40-1.
2. Sterling M, Jull G, Wright A. Cervical mobilisation: concurrent effects on pain, sympathetic nervous system activity and motor activity. *Man Ther* 2001;6(2):72-81.
3. Vicenzino B, Collins D, Benson H, Wright A. An investigation of the interrelationship between manipulative therapy-induced hypoalgesia and sympathoexcitation. *J Man Physiol Ther* 1998; 21(7):448-53.
4. McGuinness J, Vicenzino B, Wright A. Influence of a cervical mobilisation technique on respiratory and cardiovascular function. *Man Ther* 1997;2(4):216-20.
5. Maitland GD, Banks K, English K, Hengeveld E, editors. *Maitland's vertebral manipulation*. 6th ed. Boston: Butterworth-Heinemann; 2001.

#### [The author responds:]

The comments by Meena Sran and Karim Khan offer an important clarification. The risks of mobilization seems indeed to be much smaller than those of spinal manipulation, though truly convincing data are not presently available. I was interested to learn that

many Canadian physiotherapists have training in both methods and "select the most appropriate technique for the patient's problem." This begs the question of how the most appropriate technique is determined. A recent analysis<sup>1</sup> of 64 previously unpublished cases of complications after upper spinal manipulations demonstrated that no factors are identifiable from the clinical history or physical examination of the patients that would help isolate patients at risk. Essentially, this means everyone is at risk. Spinal manipulation is undoubtedly the mainstay of chiropractors, and it is not surprising that the vast majority of complications happen in the hands of chiropractors.<sup>2</sup> In my personal experience, physiotherapists in Europe use spinal manipulation less frequently and with more discrimination than chiropractors in Canada.

#### Edzard Ernst

Department of Complementary Medicine  
School of Sport and Health Sciences  
University of Exeter  
Exeter, UK

#### References

1. Haldeman S, Kohlbeck FJ, McGregor M. Unpredictability of cerebrovascular ischemia associated with cervical spine manipulation therapy. *Spine* 2002;27:49-55.
2. Di Fabio RP. Manipulation of the cervical spine risks and benefits. *Phys Ther* 1999;79:50-65.

### Clinical practice guidelines: breast cancer pain

It is disturbing to read the 2001 update of the clinical practice guideline on the management of chronic pain in patients with breast cancer as summarized in *CMAJ* by Chris Emery and colleagues.<sup>1</sup> In the full text of these guidelines the authors state that bone pain from vertebral metastases is very common; however, there is absolutely no mention of surgical stabilization techniques despite the fact that they are an effective evidence-based option for treating mechanical axial skeletal pain due to bone metastases.

Among their descriptions of treatment options the authors are careful to include descriptions of complementary techniques with little or no evidence for their effectiveness, including neurosurgical ablative procedures such as rhizotomy and cordotomy, and psychotherapy. They fail to mention the excellent outcomes seen with surgical stabilization of pathological vertebral fractures and impending fractures. They even state that "except for spinal cord compression, neurosurgical interventions are rarely required in the management of cancer pain." There is now a large body of literature that supports the surgical decompression and stabilization of spinal metastases as effective palliation of mechanical pain (not only for metastatic epidural spinal cord compression) with acceptable levels of morbidity.<sup>2-5</sup> In fact, surgery followed by radiation appears to be more effective than radiation alone in improving local pain control and survival and reducing postoperative morbidity.<sup>2-6</sup>

No longer is it acceptable practice to deny surgical stabilization to appropriate patients with vertebral metastases. At the Combined Neurosurgical and Orthopaedic Spine Program at Vancouver General Hospital we have reported favourable outcomes in these surgically treated patients; we continue to follow their outcomes prospectively and are performing an economic evaluation of surgical treatment in these patients. It is a pity that the guidelines published by Emery and colleagues continue to perpetuate the lack of appropriate referral and access to effective spinal surgical care for this often inadequately palliated patient population.

#### Marcel Dvorak

#### Charles G. Fisher

Combined Neurosurgical and  
Orthopaedic Spine Program  
Vancouver General Hospital  
Vancouver, BC

#### References

1. Emery C, Gallagher R, Hugi M, Levine M, for the Steering Committee on Clinical Practice Guidelines for the Care and Treatment of Breast Cancer. Clinical practice guidelines for the care